FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
10/18/2025
Back to search
Official data from USPTO
VIVOPHARM
Did you know this trademark is already registered in United States?
Before investing in name, identity, and promotion, validate collision risk and registration strategy to avoid wasting time and budget.
Active USPTO registrationType: CombinedOffice: US
Risk and opportunity diagnosis
Executive reading for naming, filing, and monitoring decisions.
USPTO status
Active USPTO registration
Case type
Application and registration
Recorded events
34
Latest update
04/03/2026
Classification
Registered
Trademark type
Combined
Nice classes
42
Filing date
11/08/2023
Registration date
03/18/2025
Expiration date
-
Recommended action
Perform a full collision analysis and validate classes before any filing or trademark investment.
Next step
These are the details of the registration process. Even so, constant monitoring is what ensures peace of mind that your main asset remains protected.
Complete case details
Structured fields from the responsible authority and the official record.
Status date
03/18/2025
Last transaction
04/03/2026
Responsible office
United States Patent and Trademark Office
Status code
700
Official register
Principal Register
Drawing code
3
Owner type
82
Owner location
AU
Examiner
CREEF, DAVIS W
Law office
N70
Current location
FILE REPOSITORY (FRANCONIA)
Mark description
The mark consists of the stylized wording "VIVOPHARM" with "VIVO" appearing in red and "PHARM" appearing in blue, to the right of which is the design of an incomplete angled circle made of two curved lines, with the left curve being gray and the right being blue. The letters "RM" intersect with the circle.
Holders and representatives
Holders
VivoPharm Pty Ltd
Representatives
Gabrielle A. Holley Holley & Menker, P.A.
Technical classification
Nice Classes
Class 42
Vienna Codes
No Vienna codes available.
Goods and services
Class 42
Research and development in relation to pharmaceuticals; pre-clinical studiestesting and evaluation relating to the efficacytoxicology and safety of pharmaceutical treatmentsin particular bioanalytical studies of pharmaceutical treatments; design of testsevaluations and studies in relation to the efficacytoxicology and safetyin particular bioanalytic studies of pharmaceuticals being pharmaceutical product evaluation; scientific and technological servicesanalysis of statistical data and preparation of reports in the fields of medical and scientific research; provision of consultancyinformation and advisory services in relation to the foregoing
Publications
History of USPTO decisions and trademark events.
34 publications found
FICS
FINAL DISPOSITION NOTICE SENT TO IB
09/25/2025
FIMP
FINAL DISPOSITION PROCESSED
09/25/2025
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
06/18/2025
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
05/31/2025
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
05/13/2025
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
05/13/2025
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
03/18/2025
R.PR
REGISTERED-PRINCIPAL REGISTER
03/18/2025
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
01/28/2025
PUBO
PUBLISHED FOR OPPOSITION
01/28/2025
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
01/22/2025
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
01/02/2025
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
10/10/2024
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
09/02/2024
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
09/02/2024
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
09/02/2024
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
07/30/2024
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
07/30/2024
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
07/30/2024
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
07/30/2024
CHAN
APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
07/30/2024
COAR
TEAS CHANGE OF OWNER ADDRESS RECEIVED
07/30/2024
RFNT
REFUSAL PROCESSED BY IB
07/28/2024
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
07/08/2024
RFRR
REFUSAL PROCESSED BY MPU
07/08/2024
LIME
LIMITATION FROM THE IB - REQUEST EXAM REVIEW
07/07/2024
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
06/19/2024
CNRT
NON-FINAL ACTION WRITTEN
06/18/2024
DOCK
ASSIGNED TO EXAMINER
06/17/2024
LIMG
LIMITATION OF GOODS RECEIVED FROM IB
05/12/2024
MAFR
APPLICATION FILING RECEIPT MAILED
12/19/2023
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
12/15/2023
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
12/14/2023
Continuous trademark protection
Get notified about every new filing that threatens VIVOPHARM or your mark.
Professional 24-month watch service: we monitor USPTO for you and alert you in time to oppose — before conflicts become losses.